Definium’s Phase 3 LSD Drug Clears a Major Depression Test
Definium Therapeutics said a single dose of its LSD based pill, DT120 ODT, reduced depression symptoms in a phase 3 trial of adults with major depressive disorder. The result gives the psychedelic field one of its clearest late stage signals yet. It also raises a practical issue for regulators, clinicians and patients. A classic psychedelic is now moving through the prescription drug system with data from a controlled, late stage trial.
New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
Key Takeaways
| Key takeaway | What it means |
|---|---|
| Drug tested | DT120 ODT, an orally dissolving form of lysergide, better known as LSD |
| Trial | Emerge, a randomized, double blind, placebo controlled phase 3 study |
| Participants | 149 adults with major depressive disorder |
| Main result | 8.1 point improvement over placebo on the MADRS depression scale at week 6 |
| Durability | Benefit remained at week 12, with a 7.3 point advantage over placebo |
| Safety | Most side effects were mild to moderate and occurred on dosing day |
| Next step | Definium is running a second late stage depression trial |
A Fast Signal From One Dose
The Emerge study tested DT120 ODT 100 micrograms against placebo. The main goal was change on the Montgomery Åsberg Depression Rating Scale at week 6. Definium reported an 8.1 point placebo adjusted improvement, with a p value below 0.0001. That means the result was unlikely to be due to chance.
The company also said patients improved quickly. At week 1, the DT120 group showed a 14.2 point advantage over placebo. By week 12, the advantage was still 7.3 points. For a field often criticized for small studies and fragile expectations, those numbers will draw attention.
Why This Trial Matters
DT120 ODT is not a microdose. It is a pharmaceutical formulation of lysergide, the compound widely known as LSD. It belongs to the classic psychedelic class, which can temporarily alter perception, mood and thinking.
The format also matters. Definium describes DT120 ODT as an orally disintegrating tablet designed for faster absorption and improved bioavailability. In plain terms, this is not a retreat style psychedelic experience. It is a controlled drug product being tested inside the FDA trial system.
Safety Remains the Next Big Question
Definium said the drug was generally well tolerated. According to the company, 99 percent of treatment emergent adverse events were mild to moderate. Most occurred on the day of dosing. The company also reported no serious safety concerns and no increase in suicidal thinking.
That is encouraging, but it is not the same as approval. These are topline results, not a full peer reviewed paper. Clinicians will want more detail on monitoring, patient selection, durability and real world use. They will also want to know how this model compares with existing antidepressants and newer interventional treatments.
What Happens Next
The result moves Definium closer to a potential FDA submission, but the story is not finished. The company is also running Ascend, a second phase 3 trial in major depressive disorder. That study is expected to enroll about 175 participants in the United States.
For patients, the larger message is cautious but meaningful. Psychedelic medicine is no longer only a question of promise. It is now producing late stage data that regulators can evaluate. The next test will be whether that data holds up across another trial, a full review and the realities of clinical care.
